Polycystic kidney disease: Tolvaptan in ADPKD - TEMPO 3:4 trial results

Nature Reviews Nephrology

Volumn 9, Issue 1, 2013, Pages 1-

  Kelsey, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TOLVAPTAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; LONG TERM CARE; NOCTURIA; NONHUMAN; NOTE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY FREQUENCY;

EID: 84871609169     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.236     Document Type: Note

References (2)

1. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. doi:10.1056/NEJMoa1205511
2. Gattone, V. H. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 24, 309-318 (1999)